HRP20050265B1 - Postupci povećanja proizvodnje trombocita i matičnih hematopoetskih stanica - Google Patents

Postupci povećanja proizvodnje trombocita i matičnih hematopoetskih stanica

Info

Publication number
HRP20050265B1
HRP20050265B1 HRP20050265AA HRP20050265A HRP20050265B1 HR P20050265 B1 HRP20050265 B1 HR P20050265B1 HR P20050265A A HRP20050265A A HR P20050265AA HR P20050265 A HRP20050265 A HR P20050265A HR P20050265 B1 HRP20050265 B1 HR P20050265B1
Authority
HR
Croatia
Prior art keywords
stem cell
hematopoietic stem
methods
cell production
increasing platelet
Prior art date
Application number
HRP20050265AA
Other languages
English (en)
Inventor
Kenneth Kaushansky
Brian R. Macdonald
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Publication of HRP20050265A2 publication Critical patent/HRP20050265A2/xx
Publication of HRP20050265B1 publication Critical patent/HRP20050265B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Prikazani izum predstavlja postupak povećanja proizvodnje matične hematopoetske stanice. Postupak obuhvaća primjenu TPO mimetičkog spoja kod subjekta. Isto su tako prikazani farmaceutski pripravci koji sadrže TPO mimetički spoj i farmaceutski prihvatljivi nosač.
HRP20050265AA 2002-09-18 2005-03-18 Postupci povećanja proizvodnje trombocita i matičnih hematopoetskih stanica HRP20050265B1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41177902P 2002-09-18 2002-09-18
US41170002P 2002-09-18 2002-09-18
PCT/US2003/029701 WO2004026332A1 (en) 2002-09-18 2003-09-18 Methods of increasing platelet and hematopoietic stem cell production

Publications (2)

Publication Number Publication Date
HRP20050265A2 HRP20050265A2 (en) 2006-06-30
HRP20050265B1 true HRP20050265B1 (hr) 2016-05-20

Family

ID=32033567

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050265AA HRP20050265B1 (hr) 2002-09-18 2005-03-18 Postupci povećanja proizvodnje trombocita i matičnih hematopoetskih stanica

Country Status (19)

Country Link
US (2) US8067367B2 (hr)
EP (2) EP1542714B1 (hr)
JP (2) JP2005539082A (hr)
KR (1) KR20050093759A (hr)
AU (2) AU2003275077B2 (hr)
BR (1) BR0314591A (hr)
CA (1) CA2499625A1 (hr)
DK (1) DK1542714T3 (hr)
EA (1) EA010759B1 (hr)
ES (2) ES2462916T3 (hr)
HR (1) HRP20050265B1 (hr)
IL (1) IL167498A (hr)
IS (1) IS7756A (hr)
MX (1) MXPA05003057A (hr)
NO (1) NO333928B1 (hr)
NZ (1) NZ566812A (hr)
PL (1) PL376085A1 (hr)
PT (1) PT1542714E (hr)
WO (1) WO2004026332A1 (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
MXPA05003057A (es) 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
KR101183875B1 (ko) * 2003-08-28 2012-09-27 오르토-맥네일 파마슈티칼, 인코퍼레이티드 수용체에 결합하는 펩티드 및 화합물
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US7615533B2 (en) * 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
JP5085322B2 (ja) 2005-06-10 2012-11-28 中外製薬株式会社 ｓｃ（Ｆｖ）２を含有する医薬組成物
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
PL1984014T3 (pl) * 2006-02-14 2015-02-27 Janssen Pharmaceutica Nv Zastosowanie peptydowych związków TPO i kompozycji farmaceutycznych w leczeniu niedokrwistości
RU2009100930A (ru) * 2006-06-14 2010-07-20 Чугаи Сейяку Кабусики Кайся (Jp) Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток
WO2013155347A1 (en) * 2012-04-11 2013-10-17 Izumi Raquel Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
WO2015120197A1 (en) * 2014-02-05 2015-08-13 Regents Of The University Of California Rna editing biomarkers for diagnosis, pharmacological screening and prognostication in cancer
CN107405331A (zh) * 2014-12-12 2017-11-28 联邦科学和工业研究组织 使用α9整联蛋白拮抗剂从骨髓干细胞龛迁移和释放HSC
SG11201710342TA (en) * 2015-06-16 2018-01-30 Univ Kyoto Method for producing highly functional platelets
WO2023056444A1 (en) * 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
WO2010021180A1 (ja) * 2008-08-22 2010-02-25 シャープ株式会社 画像信号処理装置、画像信号処理方法、画像表示装置、テレビジョン受像機、電子機器

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4668619A (en) 1980-10-30 1987-05-26 Miles Laboratories, Inc. Multilayer homogeneous specific binding assay device
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
CA1237998A (en) 1984-04-14 1988-06-14 Akihiro Ginnaga Method for purification of filamentous hemagglutinin
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8601279D0 (en) 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
GB2186579B (en) 1986-01-21 1990-07-25 Brian Maurice John Foxwell Improvements relating to the radio-labelling of proteins
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US5198424A (en) 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
WO1993006121A1 (en) 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5359115A (en) 1992-03-26 1994-10-25 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
DK0644771T4 (da) 1992-06-11 2006-12-27 Alkermes Inc Lægemiddelsystem til levering af erythropoietin
US5420328A (en) 1992-09-11 1995-05-30 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
NZ281482A (en) 1994-02-14 2000-09-29 Univ Washington The stimulation of erythropoiesis using thrombopoietin and erythropoietin
KR100289201B1 (ko) 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5989833A (en) 1994-09-20 1999-11-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for detection of molecules with affinity for MPL polypeptides
DE69515465T2 (de) 1994-11-04 2000-08-03 Santen Pharmaceutical Co Ltd Neue hydroxy-substituierte 1,3-dialkyl-harnstoffderivate
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
CA2194070A1 (en) 1995-04-26 1996-10-31 Haruhiko Yokoi Novel polypeptides
PE7898A1 (es) 1995-06-07 1998-03-05 Glaxo Group Ltd Peptidos compuestos que se ligan al receptor de trombopoietina
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6013067A (en) 1995-06-07 2000-01-11 Zymogenetics, Inc. Methods for increasing hematopoietic cells
YU34196A (sh) 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US20020187124A1 (en) 1995-09-27 2002-12-12 The General Hospital Corporation, A Massachusetts Corporation Asialocytokines and treatment of liver disease
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
SI2319928T1 (sl) * 1998-10-23 2013-08-30 Kirin-Amgen, Inc. Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1374890A3 (en) * 1999-01-28 2004-08-25 Board Of Regents, The University Of Texas System Thrombopoietin compositions for increasing circulating platelets
ATE350044T1 (de) * 1999-09-24 2007-01-15 Smithkline Beecham Corp Thrombopoietinmimetika
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
WO2001093900A1 (en) 2000-06-07 2001-12-13 Applied Research Systems Ars Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
EP1343808B1 (en) 2000-12-22 2006-09-13 Ipsen Manufacturing Ireland Limited Process for the synthesis of an lhrh peptide
CA2442399A1 (en) 2001-03-22 2002-10-03 Uop Llc Metallo aluminophosphate molecular sieve with cubic crystal morphology and methanol to olefin process using the sieve
MXPA05003057A (es) 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
KR101183875B1 (ko) * 2003-08-28 2012-09-27 오르토-맥네일 파마슈티칼, 인코퍼레이티드 수용체에 결합하는 펩티드 및 화합물
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
US20060210542A1 (en) 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
AU2009256465B2 (en) * 2008-06-03 2015-05-14 Janssen Pharmaceutica Nv TPO mimetic peptide for preventing hematological disorder associated with cancer treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060052A (en) * 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
WO2002078612A2 (en) * 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
WO2010021180A1 (ja) * 2008-08-22 2010-02-25 シャープ株式会社 画像信号処理装置、画像信号処理方法、画像表示装置、テレビジョン受像機、電子機器

Also Published As

Publication number Publication date
WO2004026332A1 (en) 2004-04-01
AU2010200100A1 (en) 2010-01-28
AU2003275077A1 (en) 2004-04-08
AU2010200100B2 (en) 2013-05-23
NO333928B1 (no) 2013-10-21
AU2003275077B2 (en) 2010-02-04
JP2005539082A (ja) 2005-12-22
HRP20050265A2 (en) 2006-06-30
BR0314591A (pt) 2005-08-09
EA200500375A1 (ru) 2006-06-30
JP2011057690A (ja) 2011-03-24
EA010759B1 (ru) 2008-10-30
NZ566812A (en) 2009-07-31
EP2319528A3 (en) 2011-08-31
ES2462916T3 (es) 2014-05-26
EP1542714A1 (en) 2005-06-22
NO20051841D0 (no) 2005-04-15
ES2781475T3 (es) 2020-09-02
US20110288019A1 (en) 2011-11-24
PT1542714E (pt) 2014-06-23
PL376085A1 (en) 2005-12-12
CA2499625A1 (en) 2004-04-01
KR20050093759A (ko) 2005-09-23
DK1542714T3 (da) 2014-05-26
US8067367B2 (en) 2011-11-29
EP2319528B8 (en) 2020-03-04
US20050282277A1 (en) 2005-12-22
EP1542714B1 (en) 2014-04-02
EP2319528B1 (en) 2020-01-22
IS7756A (is) 2005-03-17
NO20051841L (no) 2005-06-16
MXPA05003057A (es) 2006-04-18
IL167498A (en) 2014-01-30
EP2319528A2 (en) 2011-05-11
US8283313B2 (en) 2012-10-09

Similar Documents

Publication Publication Date Title
HRP20050265B1 (hr) Postupci povećanja proizvodnje trombocita i matičnih hematopoetskih stanica
NO20060847L (no) Substituert 2-aminotetralin til behandling av depresjon
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
ATE509533T1 (de) Canolaproteinisolat zusammensetzungen
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
HRP20030276B1 (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
UY27777A1 (es) Inhibidores de metaloproteinasa de heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida
HUP0303854A2 (hu) Szintetikus erythropoiesis-stimuláló proteinek
HUP0300148A2 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0303996A2 (hu) Vakcinakészítmények
EA200500240A1 (ru) Новый способ синтеза соединений 1,3,4,5-тетрагидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
NO20043367L (no) Oralt farmasoytisk preparat
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
BRPI0313764A2 (pt) método de preparação de composições de inalação de pó seco
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
RS51146B (sr) Novi difenil-azetidinon sa poboljšanim fiziološkim osobinama postupak za njegovu proizvodnju,lekovi koji sadrže ovo jedinjenje i njihova upotreba
SE9903291D0 (sv) New process
SE9802206D0 (sv) Novel compounds
ATE412005T1 (de) Zyklosporinanalog
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DK1525188T3 (da) Hidtil ukendte derivater af 4,4-dithiobis-(3-aminobutan-1-sulfonater) og sammensætninger, der indeholder dem
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190809

Year of fee payment: 17

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200907

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20210918